Clinical trials: Steatohepatitis, Nonalcoholic
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study…
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05560607
- Testing
- AZD7503 Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Atherosclerosis, Non-alcoholic Fatty Liver Disease
Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)
Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular…
- Trial name
- NCT01958411
- Where
- South Korea
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Korea University
Nonalcoholic Steatohepatitis
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis
To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic…
- Trial name
- NCT02442687
- Testing
- JKB-121: 5 mg twice daily, JKB-121: 10 mg twice daily
- Where
- 8 sites in United States
- Volunteers
- 65 people
- Sponsor
- Manal Abdelmalek
Non-Alcoholic Fatty Liver Disease, NAFLD
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Trial name
- SLIDE (NCT03867487)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Justin Ryder
Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and…
- Trial name
- NCT02875821
- Testing
- Ipragliflozin, metformin with pioglitazone
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Yonsei University
NAFLD, Inflammatory Bowel Diseases
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol.
- Conditions
- NAFLD, Inflammatory Bowel Diseases, Steatosis, Fibrosis, Liver
- Trial name
- PONI (NCT06814600)
- Testing
- Transient elastometry
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Non-alcoholic Fatty Liver Disease
Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease
The study searched for answers to two questions: 1-What are the plasma betatrophin levels in subjects with non-alcoholic fatty liver disease and healthy controls. 2.
- Trial name
- NCT02176811
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
- Trial name
- NCT02605616
- Testing
- AZ compound
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Alabama at Birmingham
Phenylketonurias, Non Alcoholic Fatty Liver
Walking Program in Fatty Liver Children With Phenylketonuria
phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood.
- Trial name
- NCT06718842
- Testing
- walking free online supervised program
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
MASLD, MASH
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease…
- Conditions
- MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- FASCINIT (NCT06692283)
- Testing
- denifanstat
- Sponsor
- Sagimet Biosciences Inc.
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Steatohepatitis, Nonalcoholic
Formula Diet Treatment for NASH Patients.
Non-alcoholic steatohepatitis (NASH) - also called fatty liver - is medically a serious problem because the liver tissue becomes fatty and stiff, and inflammatory reactions occur.
- Trial name
- NASH (NCT04707651)
- Testing
- Formula diet
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- West German Center of Diabetes and Health
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic…
- Trial name
- EMPA-LIVER (NCT07915596)
- Testing
- Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
- Where
- Bangladesh
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Non Alcoholic Steatohepatitis
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
The purpose of the study is to see if the drug ezetimibe is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01766713
- Testing
- Ezetimibe
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Nonalcoholic Fatty Liver Disease (NAFLD)
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease
This study will advance several goals of the NIH Action Plan: 1) establish a multidisciplinary team to develop quantitative methodologies and imaging protocols for liver, 2) validate diagnostic criteria and methodologies for…
- Trial name
- NCT01930123
- Testing
- intravenous fructose challenge, Blood Draw
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Manal F Abdelmalek
Nonalcoholic Steatohepatitis
Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)
1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2.
- Trial name
- NCT03375008
- Testing
- Imaging diagnostic and biopsy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Korea University Guro Hospital
Non-Alcoholic Fatty Liver Disease
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment.
- Trial name
- NCT06735118
- Testing
- Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yunnan Cancer Hospital
NAFLD, NASH
The European NAFLD Registry
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and…
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT04442334
- Where
- 37 sites in Belgium, Finland and 10 more
- Volunteers
- 10,000 people
- Sponsor
- Newcastle University
Non-alcoholic Fatty Liver Disease
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and…
- Trial name
- NCT02303314
- Testing
- Trigonella Foenum-graecum Seed Extract
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shiraz University of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.